Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV Non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update summary. J Oncol Pract. 2017;13(12):832–837.
   PubMed Web of Science ®Google Scholar
• Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v1–v27.
   PubMed Web of Science ®Google Scholar
• Pirker R. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr Opin Oncol. 2020;32(1):63–67.
   PubMed Web of Science ®Google Scholar
• Park CK, Oh I-J, Kim K-S, et al. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017;18(4):e289–e296.
   PubMed Web of Science ®Google Scholar
• Boucher M, Bennetts M. The many flavors of model-based meta-analysis: part I-introduction and landmark data. CPT Pharmacometrics Syst Pharmacol. 2016;5(2):54–64.
   PubMedGoogle Scholar
• Mould DR. Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther. 2012;92(3):283–286.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Gibbs M, Boyd RA, et al. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Clin Pharmacol Ther. 2011;90(6):766–769.
   PubMed Web of Science ®Google Scholar
• Fujita K, Yamamoto W, Endo S, et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci. 2008;99(5):1049–1054.
   PubMed Web of Science ®Google Scholar
• Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol. 2010;11(1):75–84.
   PubMed Web of Science ®Google Scholar
• Jeong SS, Choi PJ, Yi JH, et al. Impact of lifestyle diseases on postoperative complications and survival in elderly patients with stage I non-small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2017;50(2):86–93.
   PubMedGoogle Scholar
• Soo RA, Loh M, Mok TS, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol. 2011;6(6):1030–1038.
   PubMed Web of Science ®Google Scholar
• Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol. 2003;14(3):449–454.
   PubMed Web of Science ®Google Scholar
• Yano R, Konno A, Watanabe K, et al. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. Int J Clin Oncol. 2013;18(1):96–104.
   PubMed Web of Science ®Google Scholar
• Hilli J, Sailas L, Jyrkkiö S, et al. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol. 2011;67(6):1353–1362.
   PubMed Web of Science ®Google Scholar
• Xu B, Hu X, Zheng H, et al. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: a prospective multicenter study. Oncotarget. 2016;7(31):50643–50655.
   PubMedGoogle Scholar
• Zhang L, Lu S, Cheng Y, et al. Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med. 2021;9(4):338.
   PubMed Web of Science ®Google Scholar
• Kim KS, Oh I-J, Ban H-J, et al. Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer. Exp Ther Med. 2012;4(2):317–322.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Gallo C, Di Maio M, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer. 2004;91(12):1996–2004.
   PubMed Web of Science ®Google Scholar
• Gervais R, Ducolone A, Breton J-L, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2005;16(1):90–96.
   PubMed Web of Science ®Google Scholar
• Park SH, Choi SJ, Kyung SY, et al. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer. 2007;109(4):732–740.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug. Gan To Kagaku Ryoho. 1994;21(12):1997–2005.
   PubMedGoogle Scholar
• Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996;14(5):1649–1655.
   PubMed Web of Science ®Google Scholar
• Sugawara S, Nakagawa K, Yamamoto N, et al. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. Int J Clin Oncol. 2019;24(5):485–493.
   PubMed Web of Science ®Google Scholar